Aug 18 (Reuters) - RXi Pharmaceuticals Corp ::RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing.
Aug 18 (Reuters) - Akari Therapeutics PLC :Akari Therapeutics PLC files for mixed shelf of up to $100 million – SEC filing.
Aug 18 (Reuters) - Invitae Corp :Invitae Corp- files to say selling stockholders may sell up to an aggregate of 10.7 million shares of co's common stock - sec filing.
Aug 17 (Reuters) - Biotime Inc :Biotime inc - AgeX Therapeutics Inc, unit of co has closed its round of equity financing, raising net proceeds of $10 million.
Aug 16 (Reuters) - Medpace Holdings Inc :Medpace Holdings announces stock repurchase agreement with Cinven.Medpace Holdings Inc - Medpace has agreed to repurchase 2 million shares of Medpace's common stock, at a purchase price of $30.27 per share.Medpace Holdings Inc - Medpace intends to fund repurchase with cash on hand and borrowings under its senior secured revolving credit facility.
Aug 16 (Reuters) - Dyadic International Inc :Dyadic announces $5 million stock repurchase program.Dyadic announces $5 million stock repurchase program.Dyadic International Inc says expects to finance program from existing cash resources.
Aug 16 (Reuters) - Intec Pharma Ltd :Intec Pharma announces pricing of $50.0 million public offering of ordinary shares.Intec Pharma Ltd - Pricing of underwritten public offering of about 10.6 million of ordinary shares at a public offering price of $4.70 per ordinary share.Intec Pharma Ltd - Intends to use net proceeds from offering to fund its phase iii clinical trial for accordion pill Carbidopa/Levodopa.
Aug 16 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy.Fate Therapeutics Inc - patent covering use of prostaglandins as viral transduction enhancers for genetic modification of cd34hematopoietic cells.Fate Therapeutics Inc - patent expires in 2029, is owned by Indiana University research and technology corporand is licensed exclusively to co.
Aug 15 (Reuters) - Fibrogen Inc - :Fibrogen, Inc. announces pricing of follow-on offering of common stock.Fibrogen Inc - offering 8 million shares of its common stock at an offering price of $40.75 per share, before underwriting discounts and commissions.
Aug 15 (Reuters) - Medinet Co Ltd <2370.T>:* Says 13,500 units of its 12th series options were exercised to 1.4 million shares of its common stock from Aug. 1 to Aug. 14.* Says the shares were exercised at the price of 163 million yen in total .